Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | CTSS | P25774 | 5/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378680 | 1.00 | ATM (0.47) | ATMMAPTKMT2ATSHRHSD17B10 | |
| SCHEMBL1828340 | 0.79 | HTT (0.39) | ATMMAPTTSHRHSD17B10ALDH1A1 | |
| SCHEMBL27803425 | 0.77 | MEN1 (0.45) | ATMMAPTKMT2APPARAPPARG | |
| SCHEMBL2405973 | 0.73 | KMT2A (0.43) | ATMMAPTKMT2ATSHRHSD17B10 | |
| SCHEMBL12590862 | 0.73 | KMT2A (0.43) | ATMMAPTKMT2ATSHRHSD17B10 | |
| SCHEMBL12590864 | 0.73 | KMT2A (0.43) | ATMMAPTKMT2ATSHRHSD17B10 | |
| SCHEMBL12203593 | 0.73 | CTSK (0.62) | ATMMAPTKMT2AHSD17B10CTSS | |
| SCHEMBL6346032 | 0.73 | CTSK (0.62) | ATMMAPTKMT2AHSD17B10CTSS | |
| SCHEMBL6346030 | 0.73 | CTSK (0.62) | ATMMAPTKMT2AHSD17B10CTSS | |
| SCHEMBL506000 | 0.73 | NR1H4 (0.60) | MAPTKMT2ATSHRPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230419-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC7, BIRC3 | ATM 4271/4885MAPT 1455/4885KMT2A 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.